Jazz Pharmaceuticals plc JAZZ

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
65/100
Moderate

Ranked against 712 peers in Biotechnology

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic … Full JAZZ analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.98), suggesting sticky customer base.
  • Cash Generation Consistent Cash generation is consistent (score 0.94), indicating reliable business model.

Key risks

  • Liquidity Concerns Liquidity is concerning (score 0.20), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
58
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where JAZZ ranks in Biotechnology

Jazz Pharmaceuticals plc ranks #63 of 713 scored companies in Biotechnology by moat score — the top 9%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
59 TG Therapeutics, Inc. TGTX 66/100 Moderate
60 Karyopharm Therapeutics Inc. KPTI 66/100 Moderate
61 Kiora Pharmaceuticals, Inc. KPRX 66/100 Moderate
62 Vor Biopharma Inc. VOR 65/100 Moderate
63 Jazz Pharmaceuticals plc JAZZ 65/100 Moderate
64 Nanobiotix S.A. NBTX 65/100 Moderate
65 Immunocore Holdings plc IMCR 65/100 Moderate
66 Equillium, Inc. EQ 64/100 Moderate
67 Ionis Pharmaceuticals, Inc. IONS 64/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How JAZZ scores on the Corporate Default defenses

Pricing Power

Score 58 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 84 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 96 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 54 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 48 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 59 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding JAZZ's moat

What is Jazz Pharmaceuticals plc's moat score?

Jazz Pharmaceuticals plc (JAZZ) scores 65 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #63 of 713 scored companies in Biotechnology, the top 9%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (96/100) and its weakest is Resilience (48/100).

How does Jazz Pharmaceuticals plc compare with other Biotechnology companies?

Jazz Pharmaceuticals plc ranks #63 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Vor Biopharma Inc. (VOR) at 65 just above it and Nanobiotix S.A. (NBTX) at 65 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Jazz Pharmaceuticals plc scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Jazz Pharmaceuticals plc?

The Corporate Default template measures 6 defenses, and JAZZ scores: Pricing Power (58), Cost Advantage (84), Customer Stickiness (96), Capital Efficiency (54), Resilience (48), Scale & Market Position (59). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000